Shingles vaccination and neuroimmune vulnerability.

Area of Science:

• Neuroimmunology
• Gerontology
• Infectious Disease

Background:

• Emerging evidence links shingles vaccination to reduced dementia risk.
• Varicella-zoster virus (VZV) latency is implicated in neuroimmune vulnerability.
• Subclinical VZV reactivation may prime microglia in aging brains.

Purpose of the Study:

• To propose a mechanism where VZV reactivation amplifies neuroinflammation.
• To explore how shingles vaccination might mitigate this risk.
• To contrast this with trained immunity and discuss innate immune resolution.

Main Methods:

• This is an opinion article, presenting a theoretical framework.
• It contrasts proposed VZV reactivation mechanism with trained immunity.
• It discusses the role of microglial phagocytosis and inflammatory resolution.

Main Results:

• Subclinical VZV reactivation may act as a chronic peripheral immune stressor.
• Shingles vaccination could suppress the VZV reservoir, lowering inflammatory tone.
• Impaired innate immune clearance, not just activation, may sustain neuroinflammation.

Conclusions:

• Shingles vaccination may protect against dementia by modulating VZV-induced neuroinflammation.
• Vaccination might preserve neuroimmune balance in aging by reducing cumulative inflammatory load.
• Understanding VZV's role in neuroinflammation offers new avenues for dementia prevention.